Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes - PubMed (original) (raw)

Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes

B de Valk et al. Eur J Clin Invest. 2000 Mar.

Abstract

Background: Hereditary haemochromatosis (HH) is a common autosomal recessive disease. Recently, HH heterozygosity has been identified as an independent risk factor for myocardial infarction and cardiovascular mortality. Iron may play an important role in atherogenesis by catalyzing peroxidation of low-density-lipoprotein (LDL), an essential step in atherogenesis. In iron overload conditions, non-transferrin-bound iron (NTBI) is found in serum, which can catalyze lipid peroxidation. We investigated whether sera of HH heterozygotes contain more NTBI than sera of normal controls.

Methods: In 27 treated HH homozygotes, 22 HH heterozygotes and 17 healthy control subjects, conventional parameters of iron status (serum iron, transferrin saturation, serum ferritin) were measured. NTBI was detected using HPLC after addition of nitrilotriacetic acid and pretreatment with cobalt.

Results: The conventional parameters of iron status were similar in the HH heterozygous group and the control group. NTBI was significantly higher in homozygotes compared to heterozygotes (1.79 micromol L-1 vs. 0.51 micromol L-1, 95% CI of the difference = 0.6-1.95, P < 0.001), and controls (1.79 micromol L-1 vs. - 0.3 micromol L-1, 95% CI of the difference = 1.36-2.81, P < 0.001). The difference in NTBI between the heterozygous subjects and control subjects was also significant (0.51 micromol L-1 vs. - 0. 3 micromol L-1, 95% CI of the difference = 0.05-1.57, P < 0.05).

Conclusion: Phlebotomy treated HH homozygotes maintain a high and potentially harmful serum NTBI. HH heterozygotes have a higher serum NTBI than normal controls. The reported increased risk of cardiovascular events in heterozygous haemochromatosis may be explained by NTBI-catalyzed LDL peroxidation.

PubMed Disclaimer

Cited by

Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies.
Rombout-Sestrienkova E, Brandts L, Koek GH, van Deursen CTBM. Rombout-Sestrienkova E, et al. J Clin Apher. 2022 Feb;37(1):100-105. doi: 10.1002/jca.21956. Epub 2021 Dec 13. J Clin Apher. 2022. PMID: 34897777 Free PMC article.
Iron Absorption in Iron-Deficient Women, Who Received 65 mg Fe with an Indonesian Breakfast, Is Much Better from NaFe(III)EDTA than from Fe(II)SO₄, with an Acceptable Increase of Plasma NTBI. A Randomized Clinical Trial.
Ginanjar E, Indrawati L, Setianingsih I, Atmakusumah D, Harahap A, Timan IS, Marx JJM. Ginanjar E, et al. Pharmaceuticals (Basel). 2018 Sep 10;11(3):85. doi: 10.3390/ph11030085. Pharmaceuticals (Basel). 2018. PMID: 30201907 Free PMC article.
The Role of Iron in Atherosclerosis and its Association with Related Diseases.
Gao Y, Wang B, Hu M, Ma Y, Zheng B. Gao Y, et al. Curr Atheroscler Rep. 2024 Nov 9;27(1):1. doi: 10.1007/s11883-024-01251-1. Curr Atheroscler Rep. 2024. PMID: 39520606 Review.
Bone Microthrombus Promotes Bone Loss in Iron Accumulation Rats.
Hang HF, Dong LJ, Tang XB, Wang AF, Yang F, Zhang H, Xu YJ. Hang HF, et al. Curr Med Sci. 2020 Oct;40(5):943-950. doi: 10.1007/s11596-020-2251-8. Epub 2020 Oct 29. Curr Med Sci. 2020. PMID: 32980898
Classical and intermediate monocytes scavenge non-transferrin-bound iron and damaged erythrocytes.
Haschka D, Petzer V, Kocher F, Tschurtschenthaler C, Schaefer B, Seifert M, Sopper S, Sonnweber T, Feistritzer C, Arvedson TL, Zoller H, Stauder R, Theurl I, Weiss G, Tymoszuk P. Haschka D, et al. JCI Insight. 2019 Apr 18;4(8):e98867. doi: 10.1172/jci.insight.98867. eCollection 2019 Apr 18. JCI Insight. 2019. PMID: 30996139 Free PMC article.

Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes - PubMed (original) (raw)